Bausch + Lomb downgraded by H.C. Wainwright with a new price target
Stocks in this Quantisnow insightHealth Care
Quantisnow AI summary
H.C. Wainwright cut Bausch + Lomb to Neutral from Buy with a $22.00 price target.
Historical context for BLCO
Across the 28 sessions after earlier BLCO headlines, the stock closed higher 13 times and lower 15 times, with a median move of 1.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | BLCO | SPY |
|---|---|---|---|
| Oct 28, 2026 | Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance | +15.8% | +0.3% |
| Oct 7, 2026 | Barclays initiated coverage on Bausch + Lomb with a new price targetand 1 other headline that session | +0.9% | -0.2% |
| Oct 5, 2026 | Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28 | +0.4% | +0.7% |
| Sep 11, 2026 | Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser | -1.7% | +0.9% |
| Sep 9, 2026 | Leerink Partners initiated coverage on Bausch + Lomb with a new price target | +0.3% | -0.5% |
| Sep 2, 2026 | Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience | +0.7% | +0.4% |
Quantisnow market dataNYSE
BLCO
Bausch + Lomb Corporation
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Ophthalmic Goods
- Listed since
- 2022
Get push alerts for BLCO
Full BLCO profile on Quantisnow Follow BLCO and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time